PRL-3 EXPRESSION IN HUMAN PITUITARY ADENOMAS AND PROLACTINOMA EXPERIMENTAL MODEL: A POSSIBLE ROLE IN THE TUMORAL DEVELOPMENT

MOYANO G; GUIDO C.; PEREZ P.; GUTIÉRREZ S.; PICECH F.; PETITI, J. P.; TORRES A. I.; MUKDSI J. H.

Congreso; Reunión Conjunta de Sociedades de Biociencias; 2017

PRL-3 (phosphatase of regenerating liver 3) is a subclass of protein tyrosine phosphatases involved in proliferation, migration, invasion and growth tumor, and have been proposed as potential biomarkers of tumor progression. Our aim was to investigate whether PRL-3 is expressed in pituitary human tumor lesions evaluating its presence and correlating with some clinical-pathological parameters. Besides with the objective to analyze a possible PRL-3 participation in pituitary tumorigenesis, this phosphatase and p21 were evaluated in lactotroph tumoral experimental model. We analyzed PRL-3 in 46 human pituitary adenomas and Fisher male rats treated with estradiol benzoate (EB) during 10, 20 and 30 days (n: 9) were used. Normal human (n: 2) and rats (n: 3) pituitaries were use as control group (CG). Immunohistochemical technique was applied at photonic and electronic level and a semiquantitave study by western blot was used. Statistic analyzes: x2 for the variables: size, function and ki 67 in human adenomas. Anova-Fisher and correlate analyze in the experimental model. From the total human adenomas, PRL-3 was expressed in 22 out of 46 with immunolocalization predominantly in cytoplasmic level. Interestingly at ultraestructural level some tumors exhibited phosphatase immunolocalization at plasma membrane.There was a positive relation with tumor size (macroadenomas, x2 p